Is Crizotinib/Xalkori included in medical insurance? The latest reimbursement policy and drug purchase guide

Crizotinib is a targeted drug targeting a specific target. It is mainly used to treat patients with anaplastic lymphoma kinase (ALK)-positive or ROS1-positive metastatic non-small cell lung cancer (NSCLC). It prevents the growth and spread of cancer cells by inhibiting the proliferation signals of cancer cells caused by ALK and ROS1 gene rearrangements. Crizotinib has been widely used in many countries around the world and has also been approved in China for the treatment of certain types of lung cancer.

In China, crizotinib has been launched under the brand name XALKORI (XALKORI) and has become an important therapeutic drug for patients with ALK-positive or ROS1-positive non-small cell lung cancer. The main indication for Xalkori is the treatment of patients with advanced or metastatic non-small cell lung cancer who have ALK or ROS1 gene mutations in their tumor cells. For these patients, traditional chemotherapy has limited efficacy, and crizotinib can significantly inhibit the growth of tumor cells and effectively delay the progression of the disease by targeting ALK or ROS1 mutations.

The introduction of crizotinib provides a new treatment option for patients with non-small cell lung cancer, especially in ALK-positive and ROS1-positive patients, showing good efficacy. In clinical trials, crizotinib treatment can significantly improve the progression-free survival (PFS) of patients and improve the objective response rate (ORR). Compared with traditional chemotherapy, the side effects are also milder.

As the therapeutic effect of crizotinib is gradually verified, it has gradually entered China's medical insurance catalog and is protected by medical insurance policies. Patients can pay part or all of the drug costs within the coverage of medical insurance according to medical insurance standards, which greatly reduces the patient's treatment burden. For patients with ALK-positive or ROS1-positive non-small cell lung cancer in China, the inclusion of Xalkori in medical insurance is an important treatment breakthrough, allowing more patients to receive effective targeted therapy.

Reference materials:https://go.drugbank.com/drugs/DB08865